{
    "id": 1963,
    "name": "fallopian tube carcinoma",
    "source": "DOID",
    "definition": "A fallopian tube cancer that is located_in the fallopian tube. [url:http\\://www.cancer.gov/dictionary/?CdrID=45687]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:1963",
    "evidence": [
        {
            "id": 18684,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the inclusion of Motolimod (VTX-2337) with Doxil (pegylated liposomal-doxorubicin) did not result in improved survival in patients with either ovarian, fallopian tube, or primary peritoneal carcinoma (PMID: 28453702; NCT01666444).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5609,
                "therapyName": "Motolimod + Pegylated liposomal-doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 1963,
                "name": "fallopian tube carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8793,
                    "pubMedId": 28453702,
                    "title": "A phase 2, randomized, double-blind, placebo-\u00a0controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28453702"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00989651",
            "title": "Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3047,
                    "therapyName": "Bevacizumab + Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01145430",
            "title": "Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2167,
                    "therapyName": "Pegylated liposomal-doxorubicin + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01239732",
            "title": "A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01248962",
            "title": "Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01281514",
            "title": "Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2168,
                    "therapyName": "Carboplatin + Everolimus + Pegylated liposomal-doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01504126",
            "title": "Beta-Blocker / Ovarian",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1912,
                    "therapyName": "Propranolol",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01519869",
            "title": "Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT01607905",
            "title": "Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01669798",
            "title": "BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 831,
                    "therapyName": "Nintedanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01849874",
            "title": "A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01936974",
            "title": "(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1295,
                    "therapyName": "Bevacizumab + Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1296,
                    "therapyName": "Bevacizumab + Gemcitabine + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 1294,
                    "therapyName": "Bevacizumab + Carboplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1297,
                    "therapyName": "Bevacizumab + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01974765",
            "title": "Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02033616",
            "title": "Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7231,
                    "therapyName": "Ovapuldencel-T",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02042430",
            "title": "INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2575,
                    "therapyName": "Epacadostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02059265",
            "title": "Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02101775",
            "title": "Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1279,
                    "therapyName": "Adavosertib + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02121990",
            "title": "Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1451,
                    "therapyName": "Bevacizumab + Cisplatin + Olaparib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02122185",
            "title": "Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                },
                {
                    "id": 1827,
                    "therapyName": "Carboplatin + Docetaxel + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02122861",
            "title": "A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3271,
                    "therapyName": "ID-LV305",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02166905",
            "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 1324,
                    "therapyName": "DEC-205-NY-ESO-1 fusion protein vaccine",
                    "synonyms": null
                },
                {
                    "id": 2575,
                    "therapyName": "Epacadostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02188550",
            "title": "Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1621,
                    "therapyName": "Everolimus + Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02195973",
            "title": "Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1620,
                    "therapyName": "Paclitaxel + Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02208375",
            "title": "A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3139,
                    "therapyName": "Capivasertib + Olaparib",
                    "synonyms": null
                },
                {
                    "id": 3141,
                    "therapyName": "Olaparib + Vistusertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02272790",
            "title": "A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1194,
                    "therapyName": "Adavosertib + Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1279,
                    "therapyName": "Adavosertib + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1567,
                    "therapyName": "Adavosertib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02275039",
            "title": "p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1038,
                    "therapyName": "MVAp53",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02283658",
            "title": "Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1621,
                    "therapyName": "Everolimus + Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02316834",
            "title": "POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 682,
                    "therapyName": "Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02387125",
            "title": "A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4318,
                    "therapyName": "CMB305",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02431559",
            "title": "A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3101,
                    "therapyName": "Aldoxorubicin + Durvalumab + Motolimod",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02440425",
            "title": "Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02459301",
            "title": "Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3382,
                    "therapyName": "IPH2201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02470585",
            "title": "Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02485990",
            "title": "Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02537444",
            "title": "ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1605,
                    "therapyName": "Acalabrutinib",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02571725",
            "title": "PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8289,
                    "therapyName": "Olaparib + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02608684",
            "title": "A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3248,
                    "therapyName": "Cisplatin + Gemcitabine + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02657928",
            "title": "Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1568,
                    "therapyName": "Letrozole + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02659241",
            "title": "A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02661815",
            "title": "A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3469,
                    "therapyName": "Paclitaxel + Ricolinostat",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02764333",
            "title": "TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4180,
                    "therapyName": "Durvalumab + TPIV 200",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02833506",
            "title": "Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4460,
                    "therapyName": "NY-ESO-1 peptide vaccine + Sirolimus",
                    "synonyms": null
                },
                {
                    "id": 2696,
                    "therapyName": "NY-ESO-1 peptide vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02834975",
            "title": "Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02889900",
            "title": "Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1971,
                    "therapyName": "Cediranib + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02953457",
            "title": "Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4949,
                    "therapyName": "Durvalumab + Olaparib + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03017131",
            "title": "Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9674,
                    "therapyName": "Aldesleukin + Cyclophosphamide + Decitabine + NY-ESO-1-c259T",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03018405",
            "title": "A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5998,
                    "therapyName": "NKR-2 cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03029403",
            "title": "Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5266,
                    "therapyName": "Cyclophosphamide + DPX-Survivac + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03054909",
            "title": "QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3060,
                    "therapyName": "ALT-803",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03206047",
            "title": "Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 4693,
                    "therapyName": "Atezolizumab + Guadecitabine",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 5982,
                    "therapyName": "Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine + Guadecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03206645",
            "title": "PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6266,
                    "therapyName": "Carboplatin + Paclitaxel + PTC596",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03246074",
            "title": "Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6670,
                    "therapyName": "Fostamatinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03394885",
            "title": "Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (AdORN)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1203,
                    "therapyName": "Atezolizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03531645",
            "title": "Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3205,
                    "therapyName": "Fulvestrant + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03691376",
            "title": "Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 9697,
                    "therapyName": "NY-ESO-1 TCR CD4- CD34+ HSC",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                },
                {
                    "id": 9692,
                    "therapyName": "Autologous NY-ESO-1-specific CD8-positive T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03735589",
            "title": "Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8784,
                    "therapyName": "alphaDC1 + NK-like CTLs",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03839524",
            "title": "A Trial Evaluating TG4050 in Ovarian Carcinoma.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9165,
                    "therapyName": "TG4050",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03924245",
            "title": "Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1541,
                    "therapyName": "Entinostat",
                    "synonyms": null
                },
                {
                    "id": 8200,
                    "therapyName": "Entinostat + Olaparib",
                    "synonyms": null
                }
            ]
        }
    ]
}